Skip to main content

Fenimore Christopher R.'s Form 4/A amendment

Amended

Regeneron Pharmaceuticals, Inc. (REGN) · filed Aug 25, 2021

Accession no.
0001104659-21-109328
Filed
Aug 25, 2021
Trade date
Aug 20, 2021
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Aug 24, 2021

This filing lists 1 non-derivative transaction. It carries over 9 transactions from the original filing that it did not restate. Open-market sales total $3.13M. It was filed 5 days after the trade.

This amendment restates part of 0001237899-21-000017 (filed Aug 24, 2021). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fenimore Christopher R.CIK 0001697422Officer (SVP Controller)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 20, 2021Common StockFTax withholdingDisposed−8,719$664.85−$5,796,827.1519,020Direct

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001237899-21-000017 (filed Aug 24, 2021).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001237899-21-000017
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 20, 2021Common StockMOption exerciseAcquired+13,500$179.13+$2,418,25532,520Direct
Aug 23, 2021Common StockSSaleDisposed−4,576$655.00−$2,997,28027,944Direct
Aug 23, 2021Common StockSSaleDisposed−9$659.33F2−$5,933.9727,935Direct
Aug 23, 2021Common StockSSaleDisposed−23$660.33F3−$15,187.5927,912Direct
Aug 23, 2021Common StockSSaleDisposed−88$661.89F4−$58,246.3227,824Direct
Aug 23, 2021Common StockSSaleDisposed−1$662.78−$662.7827,823Direct
Aug 23, 2021Common StockSSaleDisposed−70$663.05F5−$46,413.527,753Direct
Aug 23, 2021Common StockSSaleDisposed−14$665.21−$9,312.9427,739Direct

Derivative securities (Table II)

Derivative transactions carried over from 0001237899-21-000017
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 20, 2021Common StockMOption exerciseDisposed−13,500$0.00$00Direct

Footnotes on the original

The footnotes that the prices of these transactions refer to on the original filing.

F2

Represents volume-weighted average price of sales of 9 shares of Company stock on August 23, 2021 at prices ranging from $659.28 to $659.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 23 shares of Company stock on August 23, 2021 at prices ranging from $660.09 to $660.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 88 shares of Company stock on August 23, 2021 at prices ranging from $661.47 to $661.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 70 shares of Company stock on August 23, 2021 at prices ranging from $663.00 to $663.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2

The amount of securities shown following the reported transaction gives effect to the other transactions reported by the Reporting Person in the Original Form 4.

Remarks

This Form 4/A amends the Form 4 filed by the Reporting Person on August 24, 2021 (the "Original Form 4") by adding a transaction inadvertently omitted from the Original Form 4.

Read the full filing on SEC EDGAR (opens in a new tab)